Additionally, there may have been reluctance to prescribe tofacitinib following the European reevaluation of May 2019 of the A3921133 clinical study, which revealed an increased risk of severe venous thromboembolism at a dosage of 10 mg twice a day compared with anti-TNF [21]. This evidence concerns the gene TNF and venous thromboembolism.